Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.
Christina S. Baik, MD, MPH
Advertisement
Articles by Christina S. Baik, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5